Incyte Corp

2026-11-03 21:41; UTC

Incyte Corp shares are declining in after-market trading, marking the fourth consecutive session of lower closes and reaching a low below Tuesday's close.

2026-11-02 20:26; UTC

Bernstein SocGen's Jeffrey Walch raises Incyte Corp's price target to $108.00 from $104.00 while maintaining a Market Perform rating.

2026-10-30 23:16; UTC

Incyte Corp shares are modestly higher in after-market hours, remaining 5.89% above their 20-day moving average and near the upper end of their one-month range.

2026-10-29 23:01; UTC

Incyte Corp is trading higher in after-market hours, reaching a high point and well above its 20-day moving average since Thursday's close.

2026-10-28 20:07; UTC

Incyte Corp shares are advancing as investors monitor the Federal Reserve's decision to maintain interest rates amid rising inflation, despite an earlier pullback.

2026-10-27 21:01; UTC

Incyte Corp shares declined in after-market trading after initially rising, reflecting significant volatility within the broader context of its one-month trading range.

2026-10-26 21:01; UTC

Incyte Corp shares advanced modestly in after-market trading, maintaining a cumulative return of 0.83% since Monday's close.

2026-10-23 20:07; UTC

Incyte Corp shares are declining amid a broader market downturn influenced by rising oil prices, inflation concerns, and geopolitical tensions.

2026-10-22 20:07; UTC

Incyte Corp shares are advancing, continuing a notable upward trajectory since Wednesday's close, reaching their peak just before the close on Thursday.

2026-10-21 20:07; UTC

Incyte Corp shares are declining, reflecting broader market weakness, and are approaching the low end of their one-month range amid a significant drop since Tuesday's close.

2026-10-20 20:08; UTC

Morgan Stanley initiates coverage on Incyte Corp with an Equalweight rating and a price target of $119.00, following the stock's prior close of $113.25.

2026-10-19 19:36; UTC

Incyte Corp will present new data on investigational therapies INCB161734 and INCA33890 at the ESMO Congress 2026, scheduled for October 23 to 27 in Madrid.

2026-10-17 00:01; UTC

Incyte Corp shares are trading lower in after-market hours, reversing an initial gain and reaching their lowest point of the day.

2026-10-16 20:13; UTC

Incyte Corp shares are modestly higher in after-market trading, maintaining a slight gain.

2026-10-15 21:03; UTC

Incyte Corp shares are advancing in after-market trading, continuing a strong performance after three consecutive sessions of gains, though still below the 20-day moving average.

2026-10-14 20:07; UTC

Truist Securities maintains Hold rating on Incyte Corp and raises price target to $115 in a report published today.

2026-10-13 20:02; UTC

Incyte Corp shares fell sharply, reaching a low point shortly after the market opened and remaining below its 20-day moving average.

2026-10-12 21:01; UTC

Incyte Corp shares declined in after-market trading, continuing a downward trend and remaining notably below its 20-day moving average.

2026-10-09 20:07; UTC

Incyte Corp shares traded roughly flat, peaking at a cumulative return of 0.90%, but remain significantly below their 20-day moving average.

2026-10-08 20:07; UTC

RBC Capital raised Incyte's price target to $114 and maintained its Sector Perform rating ahead of the company's Q3 results on October 29, 2026.

2026-10-07 21:31; UTC

Incyte Corp is trading lower in after-market hours, closing at its lowest point of the day and below its 20-day moving average.

2026-10-06 19:50; UTC

Incyte Corp shares fell sharply, extending a six-session decline amid notable volatility, with current prices significantly below the 20-day moving average.

2026-10-05 21:01; UTC

Incyte Corp is down significantly in after-market trading, marking its seventh consecutive session lower and remaining well below its 20-day moving average.

2026-10-02 23:05; UTC

Incyte Corp saw a modest increase in after-market trading, reaching its highest level since Friday's close, despite notable volatility during the session.

2026-10-01 23:15; UTC

Incyte Corp declined in after-market hours, marking its fourth consecutive session of losses and remaining significantly below its 20-day moving average.

2026-09-30 20:01; UTC

Incyte Corp shares fell sharply, remaining below their 20-day moving average and positioned near the lower end of their one-month range.

2026-09-29 20:07; UTC

Incyte Corp's shares fell sharply, reaching a midday low and finishing weaker, remaining below their 20-day moving average and near the lower end of their one-month trading range.

2026-09-28 21:01; UTC

Incyte Corp has advanced in after-market trading, reaching its highest level for the session amid broader biotechnology sector activity and remaining above its 20-day moving average.

2026-09-25 19:36; UTC

Incyte shares fell after FDA approved Atebrioz for fibrodysplasia ossificans progressiva, as traders await clarity on the drug's commercial prospects.

2026-09-24 22:01; UTC

Incyte Corp declined significantly in after-market trading, remaining well below its 20-day moving average and near the lower end of its one-month range.